Trellis Vitality Review: A Flagship NAD+ Program With No Price Ladder

Trellis Vitality (trellisvitality.com) builds its whole identity around NAD+. It is the first program on the site, the one the brand language is written around, and the one its blog writes cost explainers about. The entire published price for it is six words: treatment plans starting at $129 a month.¹

There is no table behind that number. We looked in the obvious place and then in the unobvious ones.

What "starting at $129" does and does not tell you

A "starting at" figure is only useful if you can see what it starts from. On Trellis's NAD+ program page there is no dose ladder, no strength, no volume, no vial size and no plan-length comparison — one number and a button. We pulled the site's build output, which is seven kilobytes of page logic containing no pricing at all, and then the intake payload at the company's own booking subdomain, which carries store theming and questionnaire metadata and no product prices. There is no rung table anywhere on this property.

Three other programs are priced the same way: glutathione from $93 a month, a lipo-MIC and B12 injection from $130, tesamorelin from $299. Four flagship-adjacent products, four unqualified floors.

The company's own GLP-1 page shows what it can do

This is what makes the omission interesting rather than merely disappointing.

Trellis also sells compounded semaglutide and tirzepatide, and on that page it publishes a proper table: semaglutide at $150 a month on a one-month plan, $140 on three months, $133 on six; tirzepatide at $199, $189 and $179. It labels the columns as per-month prices, states that longer plans cost less per month, and says all dosages are available at the same price. It is a genuinely well-formed price surface — no prepay total disguised as a monthly rate, no promotional first month standing in for the standing rate.

So the company knows how to publish a ladder. It did it once, for the product that is not its flagship.

Why we will not tell you that NAD+ costs $129 a month

Look at the shape of the GLP-1 table: the six-month rung sits about twelve per cent below the one-month rung. If NAD+ is structured the same way — and there is no reason to assume it is not — then $129 is most likely the longest-prepay rung and the month-to-month price is higher.

That is an inference. We have not observed it, we cannot observe it without walking an intake, and this publication does not publish inferred prices as facts. So the honest entry for Trellis on our NAD+ price index is from $129 a month; full ladder not published, and any comparison you build on the bare $129 is comparing a floor to other people's ceilings. The most common way a provider ends up looking cheapest on a price ranking is not that it is cheapest — it is that somebody filed a prepay rung, a promotional month or a membership fee as a monthly medication price.

And its blog says it publishes the thing it does not publish

Trellis runs a cost explainer about NAD+ injection pricing, updated in July 2026, and twice in that post it tells the reader that Trellis publishes its complete pricing on the program page.

It does not. The program page publishes a single "starting at" figure with nothing behind it. We are not treating that as deception — the likeliest explanation is a marketing page written to describe an intention — but it is the specific claim a reader would rely on to stop looking, and it is not true on the day we read it.

What the $129 would buy, whatever it turns out to be

An injection of a compound with no human trial behind the route.

There is no published pharmacokinetic study of subcutaneous NAD+ in people, and no randomized trial of it for energy, focus or aging. The only human study of administered NAD+ we can point to is a small pilot in which participants received a six-hour intravenous infusion, and it measured the plasma and urine metabolome rather than whether anyone felt or functioned differently.² Injection is not IV, and even the IV literature ends there. What the injection evidence actually shows is the long version.

The route with controlled human data is the oral precursor. Nicotinamide riboside is orally bioavailable and raises blood NAD+ in humans,³ does so reliably over months of dosing,⁴ and does the same in aged human skeletal muscle.⁵ The weak part is everything after the biomarker: a systematic review of precursor trials found the metabolic benefits limited and inconsistent even where NAD+ rose,⁶ and a randomized NMN trial raised NAD+ without a dramatic functional payoff.⁷

The disclosure record, which is better than the pricing

Two things here are genuinely good.

The pharmacy is named. VialsRX, a state-licensed compounding pharmacy in Houston, Texas, named in the site's own machine-readable summary file. For a compounded product this is the disclosure that matters most, because sterility and dosing accuracy live entirely with the compounder, and most operators in this category name a category rather than a facility.

The medical group and its director are named, and the NPI resolves: Arora Health & Aesthetics, LLC, medical director Dr. Sean Arora, active in the national provider registry. Coverage is stated as all fifty states.

Against that: we could not find an LLC or corporate filing name anywhere in the terms, which run to about three kilobytes of text. "No membership, no consult costs" and a free assessment are advertised on the product pages but are not corroborated in a terms document thin enough that most things are not. And the site carries a set of marketing statistics — a star rating with a patient count, an average number of weeks saved, an average annual saving in dollars — that are sourced nowhere. We do not repeat them.

The one it is not independent of

Trellis and The Edit run on the same medical group and the same medical director. They use different pharmacies — VialsRX here, The Pharmacy Hub there — and publish different prices, so they are separable products. They are not independent clinical second opinions. If you are shortlisting both to compare prescribers, you have one prescriber.

The regulatory screen

The brand, the medical group and the named pharmacy all returned zero company-column matches in the FDA's live warning-letter index when we screened them in August 2026.⁸ The screen carried a positive control — an unrelated telehealth seller with a letter on the record — which returned correctly, so the zero is a result rather than a query that failed silently.

Where it lands

Trellis is a well-documented operator that has published one excellent price table and four floors. If NAD+ is what you came for, the flagship is the product it tells you least about, and the number it does publish is the one most likely to be a prepay rung. Ask it directly what a single month costs before you start an intake, and hold the answer against Auren Rx's seven published rungs with strengths and volumes on every one and The Edit's flat $249 — both of which will tell you before you hand over a medical history.

Then ask the prior question. Every price on this page buys a delivery route nobody has measured in a person, and the cheapest evidence-backed way to raise NAD+ is still an oral precursor at a fraction of any of these figures: is NAD+ therapy worth it and is nicotinamide riboside worth it. Providers we do have a commercial relationship with are ranked and disclosed on our NAD+ rankings hub.